Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multip...

by Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L. Naylor
Published 2018-08-01

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

by Thomas F. Scott, Ray Su, Kuangnan Xiong, Arman Altincatal, Carmen Castrillo-Viguera, Maria L. Naylor
Published 2021-01-01

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

by Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L. Naylor, Li Zhu, Himanshu Naik, Cherié L. Butts
Published 2021-01-01

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

by Scott D. Newsome, Thomas F. Scott, Douglas L. Arnold, Gereon Nelles, Serena Hung, Yue Cui, Shulian Shang, Maria L. Naylor, Marcelo Kremenchutzky
Published 2018-08-01